Septerna Selects SEP-204 for Graves' Disease and TED, Plans Phase 1 in Q1 2027

What happened

Septerna selected SEP-204, an oral experimental drug, as a development candidate for Graves’ disease and thyroid eye disease. In animal studies, it restored normal T4 levels and reduced thyroid enlargement and eye protrusion. The company plans to begin a Phase 1 study in healthy volunteers in the first quarter of 2027.

Confirmed

Global impact / market context

The selection moves SEP-204 toward human testing but does not establish that it works or is safe in people. If later trials confirm the animal findings, treatment could address thyroid and eye symptoms; that could shape Septerna’s future development spending and the competitive landscape for these diseases.

Analyst inference

The reported animal findings may inform whether Septerna advances the program, while human safety and dosing results could determine further trial spending. Until people are tested, potential effects on treatment choices, future revenue, or company value remain uncertain.

Analyst inference

What to watch

1. Whether Septerna begins the planned Phase 1 study in healthy volunteers in the first quarter of 2027; the article describes this timing as an expectation. Confirmed
2. Human safety and dosing results, including whether once-daily use remains plausible; the reported 20–40-hour half-life is a projection, not a measured human result. Analyst inference
3. Whether later studies test Graves’ disease and thyroid eye disease patients and reproduce the animal improvements in T4, thyroid enlargement, and eye protrusion. Analyst inference

Evidence

• Original source link unavailable